RxDoctor Payments Data

Warren Jenkins, DO

Family Medicine · Frisco, TXNPI 1760410005

Payments from drug & device makers

$5,803in general payments, 2019–2025

Across 219 payments — averaging $26.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Novo Nordisk$620
  • Itamar Medical Inc$341
  • AstraZeneca$340
  • Lilly USA, LLC$276
  • AbbVie$235
  • plus $3K from 43 others

What the payments were for

  • Travel & lodging$1,20521%
  • Food & beverage$4,54878%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,803 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$55,977
Medicare patients
98
Services billed
1,234

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide38$39,176
CreonLipase/Protease/Amylase14$36,199
EliquisApixaban15$15,242
XareltoRivaroxaban15$15,228
MyrbetriqMirabegron20$13,480
SymbicortBudesonide/Formoterol Fumarate13$3,134
Estradiol14$1,124
Levothyroxine Sodium78$808
Losartan Potassium41$733
Testosterone11$700
Tamsulosin Hcl29$694
Rosuvastatin Calcium67$684
Metoprolol Succinate49$678
Aripiprazole12$676
Gabapentin43$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$276$39,17638 claims
AbbVieCreon$235$36,19914 claims
PfizerEliquis$95$15,24215 claims
Johnson & JohnsonXarelto$158$15,22815 claims
Astellas Pharma US IncMyrbetriq$120$13,48020 claims
AstraZenecaSymbicort$340$3,13413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Frisco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →